Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation;Pérdida de masa ósea en pacientes con cáncer de próstata sometidos a deprivación androgénica

Actas Urologicas Espanolas

Volumn 35, Issue 4, 2011, Pages 232-239

  Morote, J ^a   Planas, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Androgenic deprivation; Bisphosphonates; Bone densitometry; Denosumab; Osteoporosis; Prostate cancer

Indexed keywords

EID: 79953305814     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2011.01.008     Document Type: Short Survey

References (32)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. http://globocan.iarc.fr/ [Acceso: 19 de septiembre de 2010].
3. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005;328:679-87. (Pubitemid 40208305)
4. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157:439-44. (Pubitemid 27026812)
5. Townsend MF, Sanders WH, Northway RO, Graham Jr SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997;79:545-50. (Pubitemid 27051780)
6. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615-24.
7. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006;98:973-8. (Pubitemid 44536442)
8. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-23.
9. Jiang HX, Majumdar SR, Dick DA, Moreau M, Raso J, Otto DD, et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res. 2005;20:494-500. (Pubitemid 40297910)
10. Roche JJ, Wenn RT, Sahota O, Moran CG. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005;331:1374-9.
11. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005-7.
12. Morote J, Martínez E, Trilla E, Esquena S, Abascal JM, Encabo G, et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol. 2003;44:661-5. (Pubitemid 37542923)
13. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897-903. (Pubitemid 46657388)
14. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-64. (Pubitemid 40096612)
15. Dickman PW, Adolfsson J, Aström K, Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol. 2004;172(6 Pt 1):2208-12. (Pubitemid 39507493)
16. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129.
17. Morote J, Planas J, Raventós C, Placer J, Encabo G. Axial versus peripheral DXA scan to asses osteoporosis in prostate cancer patients. J Urol. 2010; 183(4)Suppl335. [AUA, Annual Meeting Proceedings: Abstract 858].
18. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010;183:2200-5.
19. Hussain SA,Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int. 2003;92:690-4. (Pubitemid 37475806)
20. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol. 2008;5:24-34.
21. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:6410-7. (Pubitemid 41759293)
22. Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol. 2006;175:1679-83.
23. Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69:500-4. (Pubitemid 46428384)
24. Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, et al. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 2007;99:812-5. (Pubitemid 46439570)
25. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004;64:1182-6. (Pubitemid 39647063)
26. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004;22:2546-53. (Pubitemid 41103742)
27. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169: 2008-12. (Pubitemid 36576705)
28. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038-42. (Pubitemid 46596753)
29. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146: 416-24. (Pubitemid 351650576)
30. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-55.
31. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010.
32. Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, et al. 2010. Guidelines on prostate cancer. Disponible en: http://www.uroweb.org/ guidelines/online-guidelines/ [Acceso 19 de septiembre de 2010].